Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 13/20 | 0.66 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25656107 | 0.92 | ENPP1 (0.55) | ENPP1ACHEBACE1PDGFRBAURKA | |
| SCHEMBL23762295 | 0.89 | ENPP1 (0.77) | ENPP1ACHEBACE1PDGFRBAURKA | |
| SCHEMBL25656109 | 0.89 | ENPP1 (0.64) | ENPP1ACHEBACE1PDGFRBAURKA | |
| Hydrochloric Acid SCHEMBL30117292 | 0.88 | ENPP1 (0.76) | ENPP1ACHEBACE1PDGFRBAURKA | |
| Hydrochloric Acid SCHEMBL23726498 | 0.88 | ENPP1 (0.76) | ENPP1ACHEBACE1PDGFRBAURKA | |
| SCHEMBL25656000 | 0.85 | ENPP1 (0.73) | ENPP1ACHEBACE1 | |
| SCHEMBL25656022 | 0.84 | ENPP1 (0.69) | ENPP1ACHEBACE1AURKA | |
| SCHEMBL23727128 | 0.82 | ENPP1 (0.79) | ENPP1ACHEBACE1PDGFRBAURKA | |
| SCHEMBL23726805 | 0.81 | ENPP1 (0.92) | ENPP1ACHEBACE1PDGFRBAURKA | |
| SCHEMBL25656114 | 0.80 | ENPP1 (0.67) | ENPP1ACHEBACE1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183212-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PPA1 | ENPP1 1/4885ACHE 939/4885BACE1 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.